Relevant bibliographies by topics / Deferoxamine and Deferasirox

Contents

  1. Journal articles
  2. Dissertations / Theses
  3. Book chapters
  4. Conference papers

Academic literature on the topic 'Deferoxamine and Deferasirox'

Author: Grafiati
Published: 3 June 2025
Last updated: 20 July 2025

Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles

Select a source type:

Consult the lists of relevant articles, books, theses, conference reports, and other scholarly sources on the topic 'Deferoxamine and Deferasirox.'

Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.

You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.

Journal articles on the topic "Deferoxamine and Deferasirox"

1

&NA;. "Deferasirox/deferoxamine." Reactions Weekly &NA;, no. 1357 (2011): 12. http://dx.doi.org/10.2165/00128415-201113570-00038.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Delea, T. E., K. El Ouagari, and O. Sofrygin. "Cost of Current Iron Chelation Infusion Therapy and Cost-Effectiveness of Once-Daily Oral Deferasirox in Transfusion-Dependent Thalassemia Patients in Canada." Blood 108, no. 11 (2006): 3349. http://dx.doi.org/10.1182/blood.v108.11.3349.3349.

Full text
Abstract:
Abstract Background: Deferasirox (Exjade®) is a recently approved once-daily oral chelator that has been shown to produce reductions in liver iron concentrations and serum ferritin similar to those with infusional deferoxamine (Desferal®), in patients with β-thalassemia major or sickle cell disease (SCD) and chronic iron overload from blood transfusions. The objective of this study was to estimate the cost of deferoxamine administration in Canada and evaluate the cost-effectiveness of deferasirox versus deferoxamine for chronic iron overload from blood transfusions from the Ontario provincial
APA, Harvard, Vancouver, ISO, and other styles
3

&NA;. "Deferasirox/deferiprone/deferoxamine." Reactions Weekly &NA;, no. 1312 (2010): 21. http://dx.doi.org/10.2165/00128415-201013120-00073.

Full text
APA, Harvard, Vancouver, ISO, and other styles
4

Martin, Mike G., and Murat O. Arcasoy. "Deferasirox versus deferoxamine." Blood 108, no. 2 (2006): 774–76. http://dx.doi.org/10.1182/blood-2006-02-002436.

Full text
APA, Harvard, Vancouver, ISO, and other styles
5

AHMED, A., M. KAMRAN, M. MUKHTAR, M. ALI та M. UMAIR. "COMPARISON OF DEFERASIROX AND DESFERRIOXAMINE AS IRON CHELATORS IN MULTI-TRANSFUSED PATIENTS OF Β-THALASSEMIA MAJOR". Biological and Clinical Sciences Research Journal 2023, № 1 (2023): 270. http://dx.doi.org/10.54112/bcsrj.v2023i1.270.

Full text
Abstract:
This study aimed to compare the efficacy of deferasirox and deferoxamine in improving hematological and immunological parameters in patients with transfusion-dependent β-thalassemia major. 200 patients were enrolled in the study, with 100 receiving deferasirox and 100 receiving deferoxamine. The study was conducted at Mayo Hospital, Lahore. The patients were followed up for six months, during which various hematological and immunological parameters were measured at regular intervals. The data were analyzed using appropriate statistical methods. Both deferasirox and deferoxamine effectively imp
APA, Harvard, Vancouver, ISO, and other styles
6

Pennell, Dudley J., John B. Porter, Antonio Piga та ін. "A 1-year randomized controlled trial of deferasirox vs deferoxamine for myocardial iron removal in β-thalassemia major (CORDELIA)". Blood 123, № 10 (2014): 1447–54. http://dx.doi.org/10.1182/blood-2013-04-497842.

Full text
Abstract:
Key Points In β-thalassemia major patients with severe iron burden, deferasirox was noninferior to deferoxamine for myocardial iron removal. The ejection fraction was stable during treatment for both deferasirox and deferoxamine.
APA, Harvard, Vancouver, ISO, and other styles
7

Batool, Narjis, Sadia Yasmeen, Rabia Anwar, and Zikria Saleem. "Evaluation of safety and efficacy of Deferoxamine compared with deferasirox in transfusion dependent beta thalassemia patients: a single center retrospective study." Hong Kong Journal of Paediatrics Research 4, no. 3 (2021): 42–47. http://dx.doi.org/10.37515/pediatric.5887.4303.

Full text
Abstract:
Purpose: The primary cause of mortality and morbidity in thalassemia major is iron overload. The objective of this study was to compare the safety and efficacy of deferoxamine and deferasirox in transfusion dependent beta thalassemia patients. Methods: A retrospective observational study was conducted among 178 patients. Patients were divided into two groups, deferoxamine group (90 patients) and deferasirox group (88 patients). Standardized data collection form was used to collect data. Clinical and demographic characteristics of patients were recorded by checking medical records. The collecte
APA, Harvard, Vancouver, ISO, and other styles
8

Mahmood, Abdul Kareem A., and Talib Almadany. "Combined Deferoxamine - Deferasirox in Treatment of Thalassemia Major with Iron Overload." Kufa Journal for Nursing Sciences 4, no. 1 (2014): 61–68. http://dx.doi.org/10.36321/kjns.vi20141.2447.

Full text
Abstract:
Objectives: to assess the efficacy and safety of combined Deferoxamine-defeosiraxregime and deferasiraox alone in group of thalassemia major patients Methodology: Forty two patients studied for one year, 29 patients of Deferoxamine (20mg/kg/day infusion, two days /week) and Deferasiraox. Efficacy of both regimes assessed by serum ferritin. safety assessed by liver enzyme, creatinine and blood urea. Results: Those patients who were on Deferasiraox alone showed significant them chosen for deferasiraox (40 mg/kg/day), 13 patients combined therapy reduction of serum ferritin (4482), to mean of ser
APA, Harvard, Vancouver, ISO, and other styles
9

Badeli, Hamidreza, Adel Baghersalimi, Sajjad Eslami, et al. "Early Kidney Damage Markers after Deferasirox Treatment in Patients with Thalassemia Major: A Case-Control Study." Oxidative Medicine and Cellular Longevity 2019 (April 21, 2019): 1–8. http://dx.doi.org/10.1155/2019/5461617.

Full text
Abstract:
Background. The life of patients with β-thalassemia major depends on blood transfusion. Regular blood transfusion leads to hemosiderosis in their main organs. The aim of this study was to compare the effects of deferasirox and deferoxamine on renal damage in patients with β-thalassemia major. Method. The present case-control study was conducted on 60 individuals who were referred to the 17th Shahrivar Tertiary Referral Hospital in Guilan province, Iran. In this study, patients with β-thalassemia major who used deferasirox (n=21) and patients who used deferoxamine (n=19) were evaluated. The con
APA, Harvard, Vancouver, ISO, and other styles
10

Ali, Rasul, Dler Ali, Zhyan Ahmed, Amal Ahmed, Dilvin Hassen, and Rozy Tahir. "Comparison of deferasirox and deferoxamine effect on liver enzyme activities and ferritin level in patients with beta-thalassemia." Zanco Journal of Medical Sciences 24, no. 3 (2020): 354–59. http://dx.doi.org/10.15218/zjms.2020.042.

Full text
Abstract:
Background and objective: Patients on blood transfusion may develop complications related to iron overload and the effects of chelating agents (drugs), which adversely affect the liver in thalassemia, which is a genetic blood disorder of hemoglobin synthesis that causes severe anemia. This study aimed to assess the effect of deferasirox and deferoxamine drugs on liver enzyme activities (aspartate transaminase, alanine transaminase, and alkaline phosphatase), and serum ferritin level in β_thalassemic patients. Methods: This study was carried out in Erbil city from October 2017 to February 2018.
APA, Harvard, Vancouver, ISO, and other styles
More sources

Dissertations / Theses on the topic "Deferoxamine and Deferasirox"

1

Lin, Hung-Ju, та 林宏儒. "Analysis deferoxamine, deferiprone, and deferasirox in β-thalassemia patients’ plasma by capillary electrophoresis and copper nanoclusters". Thesis, 2017. http://ndltd.ncl.edu.tw/handle/22107315691985728175.

Full text
Abstract:
博士<br>高雄醫學大學<br>藥學系博士班<br>105<br>β-Thalassemia is a hereditary hemolytic disease and prevailing in Mediterranean, Southeast Asia, etc. Taiwan is one of the prevailing area. Long-term transfusion is the major therapy for β-thalassemia patients, but also results in iron overload. There are some iron-chelating agents, including deferoxamine (DFO), deferiprone (DFR), and deferasirox (DFX) to be used to remove the excess iron. This study utilized capillary electrophoresis (CE) to monitor the concentration of DFO, DFR, and DFX in β-thalassemia patients’ plasma. In addition, copper nanocluster (CuNCs
APA, Harvard, Vancouver, ISO, and other styles

Book chapters on the topic "Deferoxamine and Deferasirox"

1

Carpenter, John P., John C. Wood, and Dudley J. Pennell. "Myocardial iron overload." In The EACVI Textbook of Cardiovascular Magnetic Resonance, edited by Massimo Lombardi, Sven Plein, Steffen Petersen, et al. Oxford University Press, 2018. http://dx.doi.org/10.1093/med/9780198779735.003.0033.

Full text
Abstract:
The heart is the target lethal organ in thalassaemia major. Cardiovascular magnetic resonance (CMR) measures iron using the magnetic relaxation time T<sub>2</sub>*. This allows comparison with the left ventricular function and conventional iron measurements such as liver iron and serum ferritin. The single breath-hold cardiac-gated CMR acquisition takes only 15 seconds, making it cost-efficient and relevant to developing countries. Myocardial T<sub>2</sub>* of &lt;20 ms (increased iron) correlates with reduced left ventricular ejection fraction, but poor correlation exists with ferritin and liver iron, indicating poor capability to assess future risk. Myocardial T<sub>2</sub>* of &lt;10 ms is present in &gt;90% of thalassaemia patients developing heart failure, and approximately 50% of patients with T<sub>2</sub>* of &lt;6 ms will develop heart failure within 1 year without intensified treatment. The technique is validated and calibrated against human heart iron concentration. The treatment for iron overload is iron chelation, and three major trials have been performed for the heart. The first trial showed deferiprone was superior to deferoxamine in removing cardiac iron. The second trial showed a combination therapy of deferiprone with deferoxamine was more effective than deferoxamine monotherapy. The third trial showed that deferasirox was non-inferior to deferoxamine in removing cardiac iron. Each drug in suitable doses can be used to remove cardiac iron, but their use depends on clinical circumstances. Other combination regimes are also being evaluated. Use of T<sub>2</sub>*, intensification of chelation treatment, and use of deferiprone are associated with reduced mortality (a reduction in deaths by 71% has been shown in the United Kingdom). The use of T<sub>2</sub>* and iron chelators in the heart has been summarized in recent American Heart Association guidelines.
APA, Harvard, Vancouver, ISO, and other styles

Conference papers on the topic "Deferoxamine and Deferasirox"

1

Oh, Go Oun, Myoung-Hee Kang, Han-Na Kang, et al. "Abstract 2132: Deferoxamine and Deferasirox enhance anticancer effects of apoptosis in gastric cancer cells." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-2132.

Full text
APA, Harvard, Vancouver, ISO, and other styles
2

Kang, Han Na, Myoung Hee Kang, Jung Lim Km, et al. "Abstract 4465: Inhibition of tumor growth, lymphangiogenesis, and metastasis by iron chelators, deferoxamine and deferasirox, in breast cancers." In Proceedings: AACR 102nd Annual Meeting 2011‐‐ Apr 2‐6, 2011; Orlando, FL. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1538-7445.am2011-4465.

Full text
APA, Harvard, Vancouver, ISO, and other styles
You might also be interested in the extended bibliographies on the topic 'Deferoxamine and Deferasirox' for particular source types:
Journal articles
We offer discounts on all premium plans for authors whose works are included in thematic literature selections. Contact us to get a unique promo code!

To the bibliography